EPS for Vertex Pharmaceuticals Incorporated (VRTX) Expected At $0.05

July 18, 2017 - By Richard Conner

 EPS for Vertex Pharmaceuticals Incorporated (VRTX) Expected At $0.05
Investors sentiment decreased to 0.88 in Q4 2016. Its down 0.22, from 1.1 in 2016Q3. It dropped, as 48 investors sold Vertex Pharmaceuticals Incorporated shares while 165 reduced holdings. 46 funds opened positions while 141 raised stakes. 232.42 million shares or 0.81% less from 234.32 million shares in 2016Q3 were reported.
Elk Creek Prns Ltd Llc has 3,110 shares. Veritable L P invested 0.01% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Blair William And Il invested in 0% or 6,121 shares. Tradewinds Capital Limited Liability reported 81 shares. Princeton Cap Mngmt invested in 23,796 shares or 1.17% of the stock. Hirtle Callaghan & Ltd Liability Corp has invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Hallmark Cap holds 0% or 32 shares in its portfolio. Advisors Asset Management has 0.03% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Putnam Invs reported 0.07% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). State Street holds 11.77 million shares. Private Advisor Group Ltd holds 0.01% or 5,234 shares in its portfolio. Piedmont Inv Limited Liability Company has invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). New York-based Edgewood Limited Company has invested 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Ny State Common Retirement Fund holds 763,300 shares. Conning owns 6,239 shares for 0.02% of their portfolio.

Since February 1, 2017, it had 0 insider buys, and 30 insider sales for $68.81 million activity. Sachdev Amit also sold $673,733 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, February 13. Another trade for 1,176 shares valued at $151,045 was made by Bhatia Sangeeta N. on Thursday, June 1. $19.05M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by LEIDEN JEFFREY M. $1.09 million worth of stock was sold by Chodakewitz Jeffrey on Tuesday, May 2. $975,000 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by ALTSHULER DAVID. Lee Yuchun sold 1,323 shares worth $169,926. SMITH IAN F sold $336,790 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, February 13.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on July, 26. They expect $0.05 EPS, up 600.00 % or $0.06 from last year’s $-0.01 per share. VRTX’s profit will be $12.46M for 646.05 P/E if the $0.05 EPS becomes a reality. After $0.13 actual EPS reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -61.54 % negative EPS growth. The stock decreased 1.36% or $1.78 during the last trading session, reaching $129.21. About 1.14M shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since July 18, 2016 and is uptrending. It has outperformed by 28.99% the S&P500.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 19 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 12 have Buy rating, 0 Sell and 7 Hold. Therefore 63% are positive. Vertex Pharmaceuticals had 43 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Hold” rating given on Monday, August 24 by Vetr. The firm earned “Outperform” rating on Friday, February 5 by Leerink Swann. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Oppenheimer on Sunday, July 9. Stifel Nicolaus maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Thursday, September 15 with “Buy” rating. Argus Research upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Monday, September 28. Argus Research has “Buy” rating and $126 target. The stock has “Mkt Perform” rating by Raymond James on Tuesday, September 13. Cowen & Co maintained it with “Hold” rating and $10500 target in Wednesday, July 5 report. The firm earned “Outperform” rating on Wednesday, January 20 by Credit Suisse. The stock has “Overweight” rating by Barclays Capital on Monday, September 14. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Outperform” rating by Leerink Swann on Tuesday, March 8.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The company has market cap of $32.20 billion. The Firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications. It has a 182.48 P/E ratio. The Company’s marketed medicines are ORKAMBI and KALYDECO.

More news for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were recently published by: Benzinga.com, which released: “2 Reasons Vertex Pharmaceuticals Just Got Upgraded” on June 23, 2017. Streetinsider.com‘s article titled: “Vertex Pharma (VRTX) Reports Reimbursement Agreement in Italy for ORKAMBI …” and published on July 13, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: